177 related articles for article (PubMed ID: 34664529)
1. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study.
Richard A; Wisniak A; Perez-Saez J; Garrison-Desany H; Petrovic D; Piumatti G; Baysson H; Picazio A; Pennacchio F; De Ridder D; Chappuis F; Vuilleumier N; Low N; Hurst S; Eckerle I; Flahault A; Kaiser L; Azman AS; Guessous I; Stringhini S
Scand J Public Health; 2022 Feb; 50(1):124-135. PubMed ID: 34664529
[No Abstract] [Full Text] [Related]
2. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
[TBL] [Abstract][Full Text] [Related]
4. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland.
Ulyte A; Radtke T; Abela IA; Haile SR; Blankenberger J; Jung R; Capelli C; Berger C; Frei A; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
BMJ Open; 2021 Jul; 11(7):e047483. PubMed ID: 34312201
[TBL] [Abstract][Full Text] [Related]
5. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.
Ulyte A; Radtke T; Abela IA; Haile SR; Berger C; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
BMJ; 2021 Mar; 372():n616. PubMed ID: 33731327
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
[TBL] [Abstract][Full Text] [Related]
7. Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland.
Baysson H; Pennachio F; Wisniak A; Zabella ME; Pullen N; Collombet P; Lorthe E; Joost S; Balavoine JF; Bachmann D; Azman A; Pittet D; Chappuis F; Kherad O; Kaiser L; Guessous I; Stringhini S;
BMJ Open; 2022 Jan; 12(1):e055515. PubMed ID: 35105645
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
Front Public Health; 2022; 10():967447. PubMed ID: 36276377
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
[TBL] [Abstract][Full Text] [Related]
12. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India.
Agarwal D; Patil R; Roy S; Kaur H; Mehandale S; Bavdekar A; Nair H; Juvekar S; Dayma G;
J Glob Health; 2023 Apr; 13():06011. PubMed ID: 37079274
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.
Hansen CB; Dvoncova K; Pérez-Alós L; Fogh K; Madsen JR; Garred CH; Jarlhelt I; Nielsen PB; Petersen SS; Fjordager CG; Lauritsen KT; Hilsted L; Boding L; Iversen KK; Hyveled L; Garred P
J Intern Med; 2023 Jun; 293(6):763-781. PubMed ID: 37024264
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.
Beretta O; Casati Pagani S; Lazzaro M; Merlani G; Bouvier Gallacchi M
Swiss Med Wkly; 2021 Dec; 151():w30116. PubMed ID: 34964622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
